A review of the two phase III studies carried out on iclaprim showed there were fewer adverse events among diabetic patients taking the drug than those on the standard of care, a treatment called Vancomycin.
Drilling down, the statistical read-out showed no patients in the iclaprim group developed kidney injury, compared with three on Vancomycin.
Additionally, only 3.6% of the iclaprim group had to be taken off the drug compared with 10% receiving the standard of care.
Separately, surveillance data from work performed in the lab has confirmed iclaprim has the potential to work against a wide variety of Gram-positive bacteria, including drug-resistant strains.
Need for new antibiotics
"Given the worldwide crisis in antibiotic resistance, there remains a major need for new antibiotic treatments,” said David Huang, Motif’s chief medical officer.
“We have shown comprehensive data indicating that iclaprim has potent activity against a wide variety of Gram-positive bacteria, including MRSA that cause severe skin infections.”
The latest statistical update will be presented later Wednesday at an industry conference being held in Lisbon.
After successfully negotiating two phase III clinical trials a new drug submission has been made to the US Food & Drug Administration, which will come back with a decision on iclaprim in February next year.
Initially, the antibiotic will be used to treat acute bacterial skin and skin structure infections.